A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension.
Renal 11beta-hydroxysteroid dehydrogenase type 2 (11betaHSD2) is an enzyme responsible for the peripheral inactivation of cortisol to cortisone in mineralocorticoid target tissues. Mutations in the gene encoding 11betaHSD2 cause the syndrome of apparent mineralocorticoid excess (AME), an autosomal recessive form of inherited hypertension, in which cortisol acts as a potent mineralocorticoid. The mutations reported to date have been confined to exons 3-5. Here, we describe two siblings, 1 and 2 yr old, who were diagnosed with hypokalemic hypertension and low plasma aldosterone and renin levels, indicating mineralocorticoid hypertension. Analysis of urinary steroid metabolites showed a markedly impaired metabolism of cortisol, with (tetrahydrocortisol + 5alpha-tetrahydrocortisol)/tetrahydrocortisone ratios of 40-60, and nearly absent urinary free cortisone. Although phenotypically normal, the heterozygous parents showed a disturbed cortisol metabolism. Genetic analysis of the HSD11B2 gene from the AME patients revealed the homozygous deletion of six nucleotides in exon 2 with the resultant loss of amino acids Leu(114) and Glu(115), representing the first alteration found in the cofactor-binding domain. The deletion mutant, expressed in HEK-293 cells, showed an approximately 20-fold lower maximum velocity but increased apparent affinity for cortisol and corticosterone. In contrast, two additionally constructed substitutions, Glu(115) to Gln or Lys, showed increased maximal velocity and apparent affinity for 11beta-hydroxyglucocorticoids. Functional analysis of wild-type and mutant proteins indicated that a disturbed conformation of the cofactor-binding domain, but not the missing negative charge of Glu(115), led to the observed decreased activity of the deletion mutant. Considered together, these findings provide evidence for a role of Glu(115) in determining cofactor-binding specificity of 11betaHSD2 and emphasize the importance of structure-function analysis to elucidate the molecular mechanism of AME.
Division of Nephrology and Hypertension, Inselspital, University of Berne, 3010 Berne, Switzerland.
A
A
Odermatt
B
B
Dick
P
P
Arnold
T
T
Zaehner
V
V
Plueschke
M N
MN
Deregibus
H
H
Repetto
B M
BM
Frey
F J
FJ
Frey
P
P
Ferrari
D042842:11-beta-Hydroxysteroid Dehydrogenases; D000450:Aldosterone / Q000031:analogs & derivatives* / Q000097:blood / Q000652:urine; D000595:Amino Acid Sequence; D001665:Binding Sites; D002460:Cell Line; D003345:Corticosterone / Q000378:metabolism; D003348:Cortisone / Q000378:metabolism / Q000652:urine; D004247:DNA / Q000032:analysis; D005260:Female; D017353:Gene Deletion; D015870:Gene Expression; D006720:Homozygote; D006801:Humans; D006854:Hydrocortisone / Q000378:metabolism; D006913:Hydroxysteroid Dehydrogenases / Q000737:chemistry / Q000235:genetics*; D006973:Hypertension / Q000209:etiology*; D007223:Infant; D007527:Isoenzymes / Q000737:chemistry / Q000235:genetics*; D008297:Male; D008901:Mineralocorticoids / Q000378:metabolism*; D008969:Molecular Sequence Data; D009154:Mutation; D018807:Polymorphism, Single-Stranded Conformational; D011487:Protein Conformation; D012083:Renin / Q000097:blood; D014162:Transfection
D007527:Isoenzymes; D008901:Mineralocorticoids; C013282:tetrahydroaldosterone; D000450:Aldosterone; D004247:DNA; D006913:Hydroxysteroid Dehydrogenases; D042842:11-beta-Hydroxysteroid Dehydrogenases; D012083:Renin; D003348:Cortisone; D003345:Corticosterone; D006854:Hydrocortisone